Ipca Laboratories Ltd.
NSE: IPCALAB | BSE: 524494
₹1,656.20
₹9.90
(0.60%)
As on 19-May-2026IST
Market cap
₹41,973 Cr
Revenue (TTM)
₹9,505 Cr
P/E Ratio
46.1
P/B Ratio
5.4
Div. Yield
0.2 %
Quality Score
7/10
Growth Score
7/10
Valuation Score
4/10
Momentum Score
8/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹910 Cr
-
ROE
11.9 %
-
ROCE
15.3 %
-
Industry P/E
30.79
-
EV/EBITDA
21.1
-
Debt to Equity
0.2
-
Book Value
₹307.1
-
EPS
₹41.3
-
Face value
1
-
Shares outstanding
253,704,218
10 Years Aggregate
CFO
₹7,421.05 Cr
EBITDA
₹9,276.53 Cr
Net Profit
₹5,444.40 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ipca Laboratories
| 16.7 | 12.8 | 11.1 | 18.9 | 34.9 | 8.9 | 22.0 |
|
BSE Healthcare
| 9.5 | 9.4 | 9.8 | 12.1 | 27.6 | 14.5 | 11.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ipca Laboratories
| -16.2 | 51.4 | 32.0 | -22.2 | -0.6 | 92.3 | 39.2 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ipca Laboratories
|
1,656.2 | 41,972.8 | 9,504.5 | 947.8 | 15.9 | 14.6 | 46.1 | 5.4 |
| 27,795.0 | 59,061.1 | 6,929.1 | 1,552.0 | 26.2 | 35.3 | 38.1 | 12.4 | |
| 5,470.0 | 65,368.6 | 14,252.7 | 2,424.5 | 17.5 | 19 | 27.6 | 4.7 | |
| 1,512.8 | 87,040.3 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 25 | 2.4 | |
| 428.2 | 69,366.8 | 16,927.0 | 368.8 | 8.8 | -0.6 | 179.9 | 2.0 | |
| 2,389.4 | 40,469.4 | 3,821.7 | 1,036.0 | 32.5 | 51.4 | 39.1 | 17.8 | |
| 2,287.4 | 1,04,542.4 | 27,958.0 | 5,355.5 | 26.6 | 27.4 | 19.6 | 4.7 | |
| 2,492.6 | 1,02,963.5 | 14,277.6 | 1,926.4 | 19.1 | 12.8 | 57.9 | 6.6 | |
| 1,882.3 | 4,51,590.8 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 41.4 | 5.6 | |
| 1,018.9 | 1,02,530.2 | 27,148.4 | 5,026.4 | 21.9 | 20.7 | 20.3 | 3.9 |
Shareholding Pattern
View DetailsNews & Analysis
All News
2 min read•By Value Research
Which stocks are vulnerable to Brexit?
4 min read•By Kumar Shankar Roy
5 min read•By Vikas Vardhan
3 min read•By Research Desk
5 min read•By Value Research
3 min read•By Research Desk
About Ipca Laboratories
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of... anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, and urology, as well as psychiatry, probiotics, respiratory, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India. Read more
-
Incorporated
1949
-
Chairman
Premchand Godha
-
Managing Director
Pranay Godha
-
Group
Ipca Laboratories
-
Headquarters
Mumbai, Maharashtra
-
Website
Looking for more details about Ipca Laboratories Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Ipca Laboratories
What is the current share price of Ipca Laboratories Ltd Today?
The share price of Ipca Laboratories Ltd is ₹1,656.20 (NSE) and ₹1,654.40 (BSE) as of 19-May-2026 IST. Ipca Laboratories Ltd has given a return of 34.87% in the last 3 years.
What is the current PB & PE ratio of Ipca Laboratories Ltd?
The P/E ratio of Ipca Laboratories Ltd is 46.13 times as on 19-May-2026, a 50 premium to its peers’ median range of 30.79 times.
The P/B ratio of Ipca Laboratories Ltd is 5.39 times as on 19-May-2026, a 16 premium to its peers’ median range of 4.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
51.63
|
5.48
|
|
2024
|
57.39
|
4.96
|
|
2023
|
43.62
|
3.52
|
|
2022
|
30.45
|
4.93
|
|
2021
|
10.59
|
5.13
|
What is the 52 Week High and Low of Ipca Laboratories Ltd?
The 52-week high and low of Ipca Laboratories Ltd are Rs 1,662.20 and Rs 1,251.60 as of 20-May-2026.
What is the market cap of Ipca Laboratories Ltd?
Ipca Laboratories Ltd has a market capitalisation of ₹ 41,973 Cr as on 19-May-2026. As per SEBI classification, it is a Mid Cap company.
Should I invest in Ipca Laboratories Ltd?
Before investing in Ipca Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.